Department of Neurobiology, Harvard Medical School, Boston, Massachusetts 02115, USA.
J Biol Chem. 2013 Jul 5;288(27):19343-57. doi: 10.1074/jbc.M113.479725. Epub 2013 May 15.
GABA type A receptors (GABAAR), the brain's major inhibitory neurotransmitter receptors, are the targets for many general anesthetics, including volatile anesthetics, etomidate, propofol, and barbiturates. How such structurally diverse agents can act similarly as positive allosteric modulators of GABAARs remains unclear. Previously, photoreactive etomidate analogs identified two equivalent anesthetic-binding sites in the transmembrane domain at the β(+)-α(-) subunit interfaces, which also contain the GABA-binding sites in the extracellular domain. Here, we used R-[(3)H]5-allyl-1-methyl-5-(m-trifluoromethyl-diazirynylphenyl) barbituric acid (R-mTFD-MPAB), a potent stereospecific barbiturate anesthetic, to photolabel expressed human α1β3γ2 GABAARs. Protein microsequencing revealed that R-[(3)H]mTFD-MPAB did not photolabel the etomidate sites at the β(+)-α(-) subunit interfaces. Instead, it photolabeled sites at the α(+)-β(-) and γ(+)-β(-) subunit interfaces in the transmembrane domain. On the (+)-side, α1M3 was labeled at Ala-291 and Tyr-294 and γ2M3 at Ser-301, and on the (-)-side, β3M1 was labeled at Met-227. These residues, like those in the etomidate site, are located at subunit interfaces near the synaptic side of the transmembrane domain. The selectivity of R-etomidate for the β(+)-α(-) interface relative to the α(+)-β(-)/γ(+)-β(-) interfaces was >100-fold, whereas that of R-mTFD-MPAB for its sites was >50-fold. Each ligand could enhance photoincorporation of the other, demonstrating allosteric interactions between the sites. The structural heterogeneity of barbiturate, etomidate, and propofol derivatives is accommodated by varying selectivities for these two classes of sites. We hypothesize that binding at any of these homologous intersubunit sites is sufficient for anesthetic action and that this explains to some degree the puzzling structural heterogeneity of anesthetics.
GABA 型 A 受体(GABAAR)是大脑主要的抑制性神经递质受体,也是许多全身麻醉剂的作用靶点,包括挥发性麻醉剂、依托咪酯、异丙酚和巴比妥类药物。如此结构多样的药物如何作为 GABAAR 的正变构调节剂发挥类似作用仍不清楚。先前,光活性依托咪酯类似物在β(+)-α(-)亚基界面的跨膜域中鉴定出两个等效的麻醉结合位点,该位点也包含细胞外域中的 GABA 结合位点。在这里,我们使用 R-[(3)H]5-烯丙基-1-甲基-5-(m-三氟甲基重氮基苯)巴比妥酸(R-mTFD-MPAB),一种有效的立体特异性巴比妥类麻醉剂,对表达的人α1β3γ2GABAAR 进行光标记。蛋白微测序显示,R-[(3)H]mTFD-MPAB 不会对β(+)-α(-)亚基界面处的依托咪酯结合位点进行光标记。相反,它在跨膜域的α(+)-β(-)和γ(+)-β(-)亚基界面处进行光标记。在 (+)-侧,α1M3 被标记在 Ala-291 和 Tyr-294,γ2M3 被标记在 Ser-301,而在 (-)-侧,β3M1 被标记在 Met-227。这些残基与依托咪酯结合位点的残基一样,位于跨膜域靠近突触侧的亚基界面处。R-依托咪酯对β(+)-α(-)界面的选择性相对于α(+)-β(-)/γ(+)-β(-)界面>100 倍,而 R-mTFD-MPAB 对其结合位点的选择性>50 倍。每种配体都可以增强另一种配体的光掺入,表明这些位点之间存在变构相互作用。巴比妥类、依托咪酯和丙泊酚衍生物的结构异质性通过对这两类结合位点的不同选择性来适应。我们假设,结合在这些同源亚基间的任何一个位点都足以发挥麻醉作用,这在一定程度上解释了麻醉剂令人困惑的结构异质性。